Global Vaccines Market Size, Trends & Growth Opportunity, By Type, By Route of Administration, By Valence, By COVID-19 Vaccines into Prevalence, and By Region and Forecast till 2027.

The Global Vaccines as a Service market was valued at USD 41.4 billion in 2020 which expected to reach USD 67.2 billion by 2027 at a CAGR 10.2% from 2020-2027.

A vaccine is a substance that is introduced into the body to prevent infection or to control disease due to a certain pathogen, which is a disease-causing organism, such as a virus, bacteria, or parasite. By inducing an immune response, the vaccine teaches the body how to defend itself against the pathogen. Preventive vaccines work by introducing a small component or a non-harmful form of the pathogen (called the foreign antigen) into the body to protect an individual from infection or disease. The body generates antibodies (via the humoral response), killer cells (via the cell mediated response), or both in response to the pathogen.

Drivers:

The global vaccines market is expected to grow due to the high prevalence of diseases that require vaccine administration and the growing use of vaccines for various infectious diseases such as influenza, pneumonia, and rotavirus infection. Furthermore, governments' emphasis on immunisation programmes helps to raise public awareness about vaccine safety and availability. Furthermore, various technologies used in the development of effective vaccines contribute to the growth of the vaccine market.

Restraints:

These lengthy vaccine development timelines stifle the development of new vaccines, limiting market growth. The decline is primarily due to drug supply and demand failures caused by the COVID-19 outbreak around the world. Market growth is being hampered by biologic drug shortages caused by insufficient biologics production.

Impact of Covid-19

The majority of markets, including the vaccine market, are declining as a result of the outbreak. The pandemic has had a negative impact on the global vaccine market, as most countries have implemented lockdown measures to combat the outbreak. Additionally, the contributions of the companies are collaborating to accelerate the development, manufacture, and delivery of COVID-19 vaccines, diagnostics, and treatments.

Market Segmentation

Segmentation By Type: Global Vaccine Market is classified on the basis of Type into Live Attenuated Vaccines, Inactivated Vaccines, Subunit and Conjugate vaccines, Toxoid Vaccines, and Combination Vaccines.
Segmentation By Route of Administration: Global Vaccine Market is classified on the basis of Route of Administration into Intramuscular, Subcutaneous, Oral, and Other Routes of Administration.
Segmentation By Valence: Global Vaccine Market is classified on the basis of Valence into Monovalent and Polyvalent (Multivalent).
Segmentation By COVID-19 Vaccines Market: Global Vaccine Market is classified on the basis of COVID-19 Vaccines into Prevalence, COVID-19 Vaccines Market Size and Forecast, Initiatives for Coronavirus Vaccine Development, Authorized Vaccines & Phase 3 Vaccine Candidates, COVID-19 Vaccine Pipeline Analysis, Purchase Data for Covid-19 Vaccines, and Vaccination Coverage.
Segmentation By Region: Global Vaccine Market is classified on the basis of Region into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape: The key players of Global Vaccine Market are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.).

Industrial Development

In October 2021, the US Food and Drug Administration (FDA) granted Pfizer an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for children aged 5 to 11.
In August 2021, the Pfizer-BioNTech COVID-19 vaccine COMIRNATY was given full US FDA approval for people aged 16 and up.
Shingrix (Zoster Vaccine Recombinant, Adjuvanted) was approved by the US Food and Drug Administration in July 2021 for the prevention of shingles (herpes zoster) in adults aged 18 and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by a known disease or therapy.

Market Taxonomy

By Type

Live Attenuated Vaccines
Inactivated Vaccines
Subunit and Conjugate vaccines
Toxoid Vaccines
Combination Vaccines

By Route of Administration

Intramuscular
Subcutaneous
Oral
Other Routes of Administration

By Valence

Monovalent
Polyvalent (Multivalent)

By COVID-19 Vaccines Market

Prevalence
COVID-19 Vaccines Market Size and Forecast
Initiatives for Coronavirus Vaccine Development
Authorized Vaccines & Phase 3 Vaccine Candidates
COVID-19 Vaccine Pipeline Analysis
Purchase Data for Covid-19 Vaccines
Vaccination Coverage

By Region

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Key Questions Addressed by the Report

What are the Key Opportunities in Global Vaccines Market?
What will be the growth rate from 2020 to 2027?
Which segment/region will have highest growth?
What are the factors that will impact/drive the Market?
What is the competitive Landscape in the Industry?
What is the role of key players in the value chain?

Frequently Asked Questions about the Global Vaccines Market

What is the estimated value of the Global Vaccines Market?

The Global Vaccines Market was estimated to be valued at $24.3 Billion in 2020.

What is the growth rate of the Global Vaccines Market?

The growth rate of the Global Vaccines Market is 6.2%, with an estimated value of $37 Billion by 2027.

What is the forecasted size of the Global Vaccines Market?

The Global Vaccines Market is estimated to be worth $37 Billion by 2027.

Who are the key companies in the Global Vaccines Market?

Key companies in the Global Vaccines Market include Sanofi (France), Merck & Co. Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co. Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia) and AstraZeneca PLC (U.K.)..

Report Attribute	Details
Published	February 2022
Forecast Period	2020 - 2027
Estimated Market Value ( USD ) in 2020	USD 24.3 Billion
Forecasted Market Value ( USD ) by 2027	USD 37 Billion
Compound Annual Growth Rate	6.2%
Regions Covered	Global
No. of Companies Mentioned	10

1 Introduction

1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope

2 Research Methodology

2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources

3 Executive Summary

4 Global Vaccine Market Outlook

4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5. Global Vaccine Market, By Type
5.1 Y-o-Y Growth Comparison, By Type
5.2 Vaccine Market Share Analysis, By Type
5.3 Vaccine Market Size and Forecast, By Type
5.3.1 Live Attenuated Vaccine
5.3.2 Inactivated Vaccine
5.3.3 Subunit and Conjugate Vaccine
5.3.4 Toxoid Vaccine
5.3.5 Combination Vaccine
6. Global Vaccine Market, By Route of Administration
6.1 Y-o-Y Growth Comparison, By Route of Administration
6.2 Vaccine Market Share Analysis, By Route of Administration
6.3 Vaccine Market Size and Forecast, By Route of Administration
6.3.1 Intramuscular
6.3.2 Subcutaneous
6.3.3 Oral
6.3.4 Other Routes of Administration
7. Global Vaccine Market, By Valence
7.1 Y-o-Y Growth Comparison, By Valence
7.2 Vaccine Market Share Analysis, By Valence
7.3 Vaccine Market Size and Forecast, By Valence
7.3.1 Monovalent
7.3.2 Polyvalent (Multivalent)
8. Global Vaccine Market, By COVID-19 Vaccines Market
8.1 Y-o-Y Growth Comparison, By COVID-19 Vaccines Market
8. Vaccine Market Share Analysis, By COVID-19 Vaccines Market
8.3 Vaccine Market Size and Forecast, By COVID-19 Vaccines Market
8.3.1 Prevalence
8.3.2 COVID-19 Vaccines Market Size and Forecast
8.3.3 Initiatives for Coronavirus Vaccine Development
8.3.4 Authorized Vaccines & Phase 3 Vaccine Candidates
8.3.5 COVID-19 Vaccine Pipeline Analysis
8.3.6 Purchase Data for Covid-19 Vaccines
9. Global Vaccine Market, By Region
9.1 Vaccine Market Share Analysis, By Region
9.2 Vaccine Market Size and Forecast, By Region
9.3 Vaccine Market Size and Forecast, By Region
10. North America Vaccine Analysis and Forecast (2021-2027)
10.1 Introduction
10.2 North America Vaccine Market Share Analysis, By Software Type
10.3 North America Vaccine Market Size and Forecast, By Route of Administration
10.4 North America Vaccine Market Size and Forecast, By Valence
10.5 North America Vaccine Market Size and Forecast, By COVID-19 Vaccines Market
10.6 North America Vaccine Market Size and Forecast, By Country
10.6.1 US
10.6.2 Canada
11. Europe Vaccine Market Analysis and Forecast (2021-2027)
11.1 Introduction
11.2 Europe Vaccine Market Share Analysis, By Software Type
11.3 Europe Vaccine Market Size and Forecast, By Route of Administration
11.4 Europe Vaccine Market Size and Forecast, By Valence
11.5 Europe Vaccine Market Size and Forecast, By COVID-19 Vaccines Market
11.6 Europe Vaccine Market Size and Forecast, By Country
11.6.1 UK
11.6.2 Germany
11.6.3 France
11.6.4 Italy
11.6.5 Spain
11.6.6 Netherland
12. Asia Pacific Vaccine Market Analysis and Forecast (2021-2027)
12.1 Introduction
12.2 Asia Pacific Vaccine Market Share Analysis, By Software Type
12.3 Asia Pacific Vaccine Market Size and Forecast, By Route of Administration
12.4 Asia Pacific Vaccine Market Size and Forecast, By Valence
12.5 Asia Pacific Vaccine Market Size and Forecast, By COVID-19 Vaccines Market
12.6 Asia Pacific Vaccine Market Size and Forecast, By Country
12.6.1 China
12.6.2 Japan
12.6.3 India
12.6.4 Australia
13. Latin America Vaccine Market Analysis and Forecast (2021-2027)
13.1 Introduction
13.2 Latin America Vaccine Market Share Analysis, By Software Type
13.3 Latin America Vaccine Market Size and Forecast, By Route of Administration
13.4 Latin America Vaccine Market Size and Forecast, By Valence
13.5 Latin America Vaccine Market Size and Forecast, By COVID-19 Vaccines Market
13.6 Latin America Vaccine Market Size and Forecast, By Country
13.6.1 Brazil
13.6.2 Rest of Latin America

14 Middle East Vaccine Market Analysis and Forecast (2021-2027)

14.1 Introduction
14.2 Middle East Vaccine Market Share Analysis, By Software Type
14.3 Middle East Vaccine Market Size and Forecast, By Route of Administration
14.4 Middle East Vaccine Market Size and Forecast, By Valence
14.5 Middle East Vaccine Market Size and Forecast, By COVID-19 Vaccines Market
14.6 Middle East Vaccine Market Size and Forecast, By Country
14.6.1 Saudi Arabia
14.6.2 UAE
14.6.3. Egypt
14.6.4. Kuwait
14.6.5. South Africa

15 Competitive Analysis

15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16. Company Profiles
16.1 Sanofi (France)
16.1.1 Overview
16.1.2 Offerings
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 Merck & Co., Inc. (U.S.)
16.2.1 Overview
16.2.2 Offerings
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3 GlaxoSmithKline plc (U.K.)
16.3.1 Overview
16.3.2 Offerings
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 AstraZeneca PLC (U.K.)
16.4.1 Overview
16.4.2 Offerings
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 CSL Limited (Australia)
16.5.1 Overview
16.5.2 Offerings
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 Takeda Pharmaceutical Company Limited (Japan)
16.6.1 Overview
16.6.2 Offerings
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 Johnson & Johnson (U.S.)
16.7.1 Overview
16.7.2 Offerings
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies